Question · asked by 1 review
Prophylactic aciclovir (oral or intravenous) vs placebo: Patient quality of life
- Population
- Patients being treated for cancer (predominantly haematological malignancies)
- Intervention
- Prophylactic aciclovir (oral or intravenous)
- Comparison
- placebo
- Outcome
- Patient quality of life
The review found no eligible studies for this question.
What each review found
Current versions only| Finding | Effect | Studies | GRADE certainty |
|---|---|---|---|
Prophylactic aciclovir (oral or intravenous) vs Placebo Patient quality of life · Patients being treated for cancer (predominantly haematological malignancies) The review found no eligible studies for this question. Interventions for the prevention and treatment of herpes simplex virus in patients being treated for cancer (2009) · Cochrane All outcomes | None of the prophylactic aciclovir versus placebo trials reported on patient quality of life. For prevention or treatment, no trials reported on duration of hospital stay, amount of analgesia or patient quality of life. | 0 studies | No studies found |
Findings are shown side by side, never pooled across reviews.
The reviews
| Review | Searched up to | Included studies | AMSTAR 2 |
|---|---|---|---|
| Interventions for the prevention and treatment of herpes simplex virus in patients being treated for cancer 2009 · Cochrane All outcomes | 2008-11 | Not listed | Not assessed |
How reviews are matched to this question
Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.